Saks, Nordstrom, Ma...
Health Care: Drugs
StemCells Inc. (STEM: NASDAQ)
$1.86 -0.04 | -2.11%
05/21/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 8.47M | 13.31M | 19.71M | 38.62M |
| Receivables | 310.95K | 268.03K | 270.03K | 766.05K |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 1.36M | 22.06K | 389.04K | 0.00 |
| Total Current Assets | 24.04M | 17.39M | 21.17M | 40.14M |
| Property, Plant & Equipment, Gross | 10.71M | 11.02M | 11.54M | 11.12M |
| Accumulated Depreciation & Depletion | 9.33M | 8.97M | 8.92M | 8.27M |
| Property, Plant & Equipment, Net | 1.38M | 2.05M | 2.63M | 2.86M |
| Intangibles | 1.82M | 2.01M | 3.00M | 3.65M |
| Other Non-Current Assets | 947.30K | 1.86M | 1.93M | 2.53M |
| Total Non-Current Assets | 6.13M | 7.82M | 9.43M | 11.05M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 30.17M | 25.21M | 30.60M | 51.19M |
| Accounts Payable | 999.36K | 1.07M | 1.10M | 890.58K |
| Short Term Debt | 213.14K | 209.23K | 244.10K | 229.25K |
| Other Current Liabilities | 0.00 | 2.60K | 0.00 | 0.00 |
| Total Current Liabilities | 5.10M | 5.65M | 5.53M | 6.53M |
| Long Term Debt | 125.00K | 331.25K | 522.50K | 698.75K |
| Deferred Income Taxes | 1.39M | 1.30M | 1.23K | 0.00 |
| Other Non-Current Liabilities | 9.56M | 7.19M | 9.05M | 13.47M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 11.09M | 8.83M | 9.59M | 14.17M |
| Total Liabilities | 16.19M | 14.48M | 15.12M | 20.70M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 13.98M | 10.73M | 15.48M | 30.50M |
| Common Par | 375.06K | 1.47M | 1.27M | 1.18M |
| Additional Paid In Capital | 374.51M | 341.81M | 325.36M | 314.94M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -361.09M | -332.60M | -311.27M | -286.03M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 193.18K | 40.71K | 119.72K | 394.72K |
| Total Capitalization | 14.11M | 11.06M | 16.00M | 31.19M |
| Total Equity | 13.98M | 10.73M | 15.48M | 30.50M |
| Total Liabilities & Stock Equity | 30.17M | 25.21M | 30.60M | 51.19M |
| Total Common Shares Outstanding | 37.51M | 22.43M | 12.73M | 11.83M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 28.82M | 14.19M | 12.33M | 10.60M |
| Diluted Weighted Shares Outstanding | 28.82M | 14.19M | 12.33M | 10.60M |
| Number of Employees | 49 | 50 | 74 | 75 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with STEM
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- User8 Stocks Under $10 Making B...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserStocks
- Contributor5 Biggest Drug-Stock Losers...
Latest STEM Headlines from TheStreet
- StemCells, Inc. Adds Byers Eye Institute At Stanford As Second Site For Phase I/II Clinical Trial In Dry Age-Related Macular Degeneration 04.18.13 | 09:04 am
- StemCells, Inc. To Participate At 2013 Regen Med Investor Day In New York 04.15.13 | 09:04 am
- StemCells, Inc. Enters Agreement To Receive $19.3 Million From California Institute For Regenerative Medicine To Help Fund IND For Alzheimer's Disease 04.11.13 | 09:04 am
- CORRECTION -- StemCells, Inc. Closes $10 Million Debt Financing 04.09.13 | 04:04 pm
- StemCells, Inc. Closes $10 Million Debt Financing 04.09.13 | 09:04 am
- StemCells, Inc. Expands Patent Portfolio 03.20.13 | 09:03 am
- StemCells, Inc. Reports Fourth Quarter And Full Year 2012 Financial Results And Provides Business Update 03.19.13 | 09:03 am
- 4 Biotech Stocks Under $5 to Watch 03.15.13 | 07:03 am
- Stocks Mixed; Dow Reclaims 14,000 02.12.13 | 02:02 pm
- StemCells, Inc. Announces First Patient Cohort Completes Spinal Cord Injury Trial - Gains In Sensory Function Persist 12 Months After Stem Cell Transplant 02.12.13 | 07:02 am
Press Releases for STEM
- Over $400 Million Raised By U.S. Life Sciences Companies Through At-the-Market (ATM) Offerings In 2012, Reports Brinson Patrick - PR Newswire 04.08.13 | 08:04 am
Partner Headlines for STEM
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- StemCells Partners With R Biomedical - Benzinga 10.30.12 | 09:10 am
- Neuralstem Swinging For The ALS Fences - Seeking Alpha 10.29.12 | 09:10 am
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- StemCells Says Achieved First Neural Stem Cell Transplant Into Patient With Sensory Function Below the Level of Injury - Benzinga 09.27.12 | 09:09 am
- Why the bear market is finally ending - NASDAQ 09.13.12 | 01:09 pm
- Today's Market News To Trade On: 5 Stocks Moving On News - Seeking Alpha 08.31.12 | 08:08 am
- Nexen ENTERS Into Agreement With CNOOC and 4 Hot Stocks On the Move - Wall St. Cheat Sheet 07.23.12 | 04:07 am
- One Stock To Buy, Two Avoids, And A Swing Trade From Last Week's Big Biotech News Movers - Seeking Alpha 07.21.12 | 06:07 am
- Healthcare Stock Insights: Vivus Wins FDA Diet Drug THUMBS UP, StemCells Give BACK - Wall St. Cheat Sheet 07.19.12 | 08:07 am
